WO2006121860A3 - Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation - Google Patents

Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation Download PDF

Info

Publication number
WO2006121860A3
WO2006121860A3 PCT/US2006/017411 US2006017411W WO2006121860A3 WO 2006121860 A3 WO2006121860 A3 WO 2006121860A3 US 2006017411 W US2006017411 W US 2006017411W WO 2006121860 A3 WO2006121860 A3 WO 2006121860A3
Authority
WO
WIPO (PCT)
Prior art keywords
glp
peptides
glucagon
peptide
receptor agonists
Prior art date
Application number
PCT/US2006/017411
Other languages
English (en)
Other versions
WO2006121860A2 (fr
Inventor
James Whelan
Kevin Lumb
Kevin Clairmont
Original Assignee
Bayer Pharmaceuticals Corp
James Whelan
Kevin Lumb
Kevin Clairmont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, James Whelan, Kevin Lumb, Kevin Clairmont filed Critical Bayer Pharmaceuticals Corp
Priority to CA002607566A priority Critical patent/CA2607566A1/fr
Priority to EP06759154A priority patent/EP1883419A4/fr
Priority to JP2008510259A priority patent/JP2008539735A/ja
Publication of WO2006121860A2 publication Critical patent/WO2006121860A2/fr
Publication of WO2006121860A3 publication Critical patent/WO2006121860A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Peptides modifiés offrant des sites de dérivatisation appropriés qui améliorent leurs propriétés pharmacocinétiques. Ces peptides GLP-1 modifiés sont des agonistes in vivo vis-à-vis du récepteur de GLP-1. Ils offrent une solution thérapeutique pour les patients à sécrétion d'insuline endogène diminuée, par exemple dans le diabète de type 2.
PCT/US2006/017411 2005-05-06 2006-05-05 Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation WO2006121860A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002607566A CA2607566A1 (fr) 2005-05-06 2006-05-05 Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation
EP06759154A EP1883419A4 (fr) 2005-05-06 2006-05-05 Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation
JP2008510259A JP2008539735A (ja) 2005-05-06 2006-05-05 グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67872305P 2005-05-06 2005-05-06
US60/678,723 2005-05-06

Publications (2)

Publication Number Publication Date
WO2006121860A2 WO2006121860A2 (fr) 2006-11-16
WO2006121860A3 true WO2006121860A3 (fr) 2007-04-12

Family

ID=37397130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/017411 WO2006121860A2 (fr) 2005-05-06 2006-05-05 Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation

Country Status (4)

Country Link
EP (1) EP1883419A4 (fr)
JP (1) JP2008539735A (fr)
CA (1) CA2607566A1 (fr)
WO (1) WO2006121860A2 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017381A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
JP2010538069A (ja) * 2007-09-07 2010-12-09 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ エキセンディン−４およびエキセンディン−３の類似体
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
CA2707448C (fr) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetiques antagoniste de glucagon et agoniste de glp-1
EP2310372B1 (fr) 2008-07-09 2012-05-23 Sanofi Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
ES2537287T3 (es) 2009-07-13 2015-06-05 Zealand Pharma A/S Análogos de glucagón acilados
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US20120282255A1 (en) * 2011-04-07 2012-11-08 Greg Plucinski Methods and compositions for the treatment of alcoholism and alcohol dependence
CA3134906A1 (fr) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Substances pharmaceutiques peptidiques ameliorees pour la resistance a l'insuline
WO2012158964A2 (fr) 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Substances pharmaceutiques peptidiques améliorées servant à lutter contre l'ostéoporose
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2844669B1 (fr) 2012-05-03 2018-08-01 Zealand Pharma A/S Composés agonistes doubles du gip-glp-1 et méthodes
FR2991055B1 (fr) * 2012-05-22 2014-06-13 C2 Diagnostics Dispositif de connexion fluidique pour appareils d'analyse biologique, composant fluidique adapte et appareil d'analyse biologique ainsi equipe;
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP2015533171A (ja) * 2012-10-11 2015-11-19 タフツ ユニバーシティー グルカゴン様ペプチド（ｇｌｐ−１）受容体アゴニスト治療剤の持続送達のための組成物および方法
EP3653649A1 (fr) 2012-11-20 2020-05-20 Mederis Diabetes, LLC Produits pharmaceutiques peptidiques améliorés pour la résistance à l'insuline
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
RS57632B1 (sr) 2013-10-17 2018-11-30 Zealand Pharma As Acilovani analozi glukagona
AU2014345569B2 (en) * 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP3066117B1 (fr) 2013-11-06 2019-01-02 Zealand Pharma A/S Composés agonistes triples glucagon-glp-1-gip
AU2015266854B2 (en) * 2014-05-28 2020-03-26 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP3985016A1 (fr) 2014-10-29 2022-04-20 Zealand Pharma A/S Composés agonistes de gip et procédés associés
EP3283507B8 (fr) 2015-04-16 2019-11-13 Zealand Pharma A/S Analogue acylé du glucagon
CA3086918A1 (fr) 2018-01-03 2019-07-11 Mederis Diabetes, Llc Composes pharmaceutiques peptidiques ameliores utilises pour le traitement d'une steatohepatite non alcoolique et d'autres troubles
SG11202009338SA (en) * 2018-03-23 2020-10-29 Carmot Therapeutics Inc Modulators of g-protein coupled receptors
KR20200141469A (ko) 2018-04-05 2020-12-18 썬 파마슈티칼 인더스트리스 리미티드 신규한 glp-1 유사체
CN108676084B (zh) * 2018-05-31 2021-12-03 长春百克生物科技股份公司 艾塞那肽的修饰物及其应用
CN109021093B (zh) * 2018-08-29 2021-09-07 上海生物制品研究所有限责任公司 聚乙二醇修饰的glp-1衍生物及其药用盐
CN111410687B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种长效glp-1化合物
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US20040127412A1 (en) * 2002-09-25 2004-07-01 Theratechnoilogies Inc. Modified GLP-1 peptides with increased biological potency
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US6887849B2 (en) * 1999-10-15 2005-05-03 Conjuchem, Inc. Long lasting synthetic glucagon-like peptide {GLP-1}

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1062240B1 (fr) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de glp-1 modifies a l'extremite n-terminale
EP1175443A1 (fr) * 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Exendines modifiees et agonistes de l'exendine
AU2003273300A1 (en) * 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CA2518336A1 (fr) * 2003-03-19 2004-11-04 Eli Lilly And Company Composes glp-1 a liaison polyethylene glycol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US6887849B2 (en) * 1999-10-15 2005-05-03 Conjuchem, Inc. Long lasting synthetic glucagon-like peptide {GLP-1}
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US20040127412A1 (en) * 2002-09-25 2004-07-01 Theratechnoilogies Inc. Modified GLP-1 peptides with increased biological potency

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1883419A4 *

Also Published As

Publication number Publication date
CA2607566A1 (fr) 2006-11-16
EP1883419A4 (fr) 2010-08-04
WO2006121860A2 (fr) 2006-11-16
JP2008539735A (ja) 2008-11-20
EP1883419A2 (fr) 2008-02-06

Similar Documents

Publication Publication Date Title
WO2006121860A3 (fr) Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation
WO2007140284A3 (fr) Modulateurs des récepteurs de glp-1 modifiés en n-terminal
WO2007121411A3 (fr) Formulations pharmaceutiques à peptide apparenté au glucagon 1(glp-1)
WO2006024275A3 (fr) Invention concernant le glp-1 et l'exendine
TW200716679A (en) N-terminally modified GLP-1 receptor modulators
WO2006014287A8 (fr) Modulateurs de glp-1 humain 1 et leur utilisation pour le traitement du diabète et de conditions connexes
ZA200606153B (en) Intranasal administration of glucose-regulating peptides
EP0997151A3 (fr) Méthode d'administration de peptides à activité insulinotropique
AU2610899A (en) N-terminally modified glp-1 derivatives
WO2003033671A3 (fr) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CY1116917T1 (el) Αναλογα οξυντομοντουλινης
WO2010013012A3 (fr) Polypeptides inédits et leurs utilisations
NZ585131A (en) Use melanocortins to treat insulin sensitivity
HK1135112A1 (en) Exendin fusion proteins
CR20190380A (es) MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR)
WO2011020319A8 (fr) Protéine de fusion régulant les lipides et le glucose du plasma, sa méthode de préparation, et ses utilisations
WO2006086727A3 (fr) Traitement des diabetes au moyen de secretagogues du glucagon-like peptide 1
NO20082958L (no) Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav for behandling av diabetes og beslektede tilstander
WO2007044591A3 (fr) Produits pharmaceutiques a base de polypeptides intestinaux vasoactifs
WO2006121588A3 (fr) Agonistes du recepteur (vpac2) du peptide activant l'adenylate cyclase hypophysaire (pacap) et leurs procedes pharmacologiques d'utilisation
EP1841781A4 (fr) Utilisation de l'il-22 pour le traitement de troubles metaboliques
NO20063801L (no) Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse
MX2022011089A (es) Peptidos como agonistas selectivos del receptor de gip.
WO2006113220A3 (fr) Mammiferes transgeniques exprimant la preproinsuline humaine
Dharanipragada Optimizing Peptides for Metabolic Diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006759154

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2607566

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008510259

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU